Telomir Pharmaceuticals Inc (TELO)

May 22, 2025

Telomir Pharmaceuticals secures $3M in straight equity sale - MSN

May 22, 2025

May 21, 2025

Telomir Pharmaceuticals secures $3 million investment By Investing.com - Investing.com Canada

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals appoints new CFO By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals appoints new CFO - Investing.com

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals raises $3 million in equity By Investing.com - Investing.com Nigeria

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale - marketscreener.com

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND - Corsicana Daily Sun

May 21, 2025

May 21, 2025

Insider Confidence: Telomir Secures $3M Premium Investment for Breakthrough Rare Disease Drug Program - Stock Titan

May 21, 2025

May 21, 2025

Telomir Pharmaceuticals raises $3 million in equity - Investing.com

May 21, 2025

May 21, 2025

EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND - Benzinga

May 21, 2025

May 20, 2025

TELO stock touches 52-week low at $2.26 amid market challenges - Investing.com Nigeria

May 20, 2025

May 19, 2025

Telomir Pharmaceuticals - The Pharma Letter

May 19, 2025

May 16, 2025

Telomir Pharma touts breakthrough in drug-resistant infections - The Pharma Letter

May 16, 2025

May 15, 2025

Telomir unveils new drug candidate against resistant bacteria By Investing.com - Investing.com South Africa

May 15, 2025

May 15, 2025

Telomir unveils new drug candidate against resistant bacteria - Investing.com Australia

May 15, 2025

May 15, 2025

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity - Jonesboro Sun

May 15, 2025

May 15, 2025

First-Ever Stable Silver(II) Drug Defeats Antibiotic-Resistant Superbugs in Groundbreaking Study - Stock Titan

May 15, 2025

May 15, 2025

Barclays PLC Raises Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

May 15, 2025

May 15, 2025

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Shares Bought by Wells Fargo & Company MN - Defense World

May 15, 2025

May 10, 2025

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Monday - Defense World

May 10, 2025

May 07, 2025

Telomir-1 shows promise in preclinical cellular aging study By Investing.com - Investing.com South Africa

May 07, 2025

May 07, 2025

Telomir-1 shows promise in preclinical cellular aging study - Investing.com Australia

May 07, 2025

May 07, 2025

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia - Weatherford Democrat

May 07, 2025

May 05, 2025

JPMorgan Chase & Co. Acquires 37,980 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

May 05, 2025

Apr 30, 2025

Geode Capital Management LLC Has $1.71 Million Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 30, 2025

Apr 28, 2025

TELO stock touches 52-week low at $2.35 amid market challenges - Investing.com

Apr 28, 2025

Apr 17, 2025

TELO stock touches 52-week low at $2.46 amid market challenges By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

TELO stock touches 52-week low at $2.46 amid market challenges - Investing.com

Apr 17, 2025

Apr 16, 2025

Corebridge Financial Inc. Has $40,000 Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 16, 2025

Apr 09, 2025

Comparing Telomir Pharmaceuticals (TELO) and The Competition - Defense World

Apr 09, 2025

Apr 08, 2025

TELO stock touches 52-week low at $2.59 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

TELO stock touches 52-week low at $2.59 amid market challenges - Investing.com

Apr 08, 2025

Apr 02, 2025

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 - ACCESS Newswire

Apr 02, 2025

Apr 02, 2025

Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 02, 2025

Apr 02, 2025

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com

Apr 01, 2025

Apr 01, 2025

Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 01, 2025

Mar 29, 2025

Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Mar 29, 2025

Mar 25, 2025

Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World

Mar 25, 2025

Mar 23, 2025

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph

Mar 23, 2025